List view / Grid view
UK National Institute for Health and Care Excellence (NICE)
Filter the results
AstraZeneca’s Calquence (acalabrutinib), a chemotherapy-free monotherapy, will be offered to patients with chronic lymphocytic leukaemia.
Zolgensma, a one-off, potentially curative treatment for type 1 spinal muscular atrophy, is set to become the most expensive drug ever approved for use on the UK’s NHS.
Pembrolizumab with pemetrexed and platinum chemotherapy has been recommended by NICE to treat non-squamous, non-small cell lung cancer.
NICE has issued final guidance recommending Beovu (brolucizumab) to treat wet age-related macular degeneration in adults.
NICE has recommended that the CAR T-cell therapy Tecartus be given to patients with relapsed or refractory mantle cell lymphoma.
The new pathway developed by NICE for medicines to go from clinical trials to NHS patients is now in action.
The ABPI has commented on the new Spending Review and outlined ways the UK government can help the life sciences sector.
The UK's NICE has recommended Emgality (galcanezumab) for the prevention of migraine in adults with episodic and chronic migraine.
More than 1,000 people each year could benefit from treatment with a combination of venetoclax and obinutuzumab, according to NICE.
NICE has recommended pembrolizumab for the treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC).
NICE has launched a public consultation for suggestions on updating how it selects the topics to develop guidance on, to improve medicine evaluations.
Tinostamustine has been granted Orphan Drug Designation by the European Commission to the treatment of T-cell prolymphocytic leukaemia (T-PLL).
NICE has said commonly used treatments for chronic primary pain such as paracetamol have little or no evidence that they work and should not be prescribed for the condition.